ImmunityBio (IBRX) Financials

$2.61 -0.08 (-2.97%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$2.62 +0.01 (+0.19%)

As of 04/25/2025 07:59 PM Eastern

Annual Income Statements for ImmunityBio

This table shows ImmunityBio's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-237	-121	-96	-96	-158	-222	-347	-417	-583	-414
Consolidated Net Income / (Loss)	-237	-121	-96	-96	-160	-224	-350	-417	-584	-414
Net Income / (Loss) Continuing Operations	-237	-121	-96	-96	-160	-224	-350	-417	-584	-414
Total Pre-Tax Income	-237	-121	-97	-97	-160	-226	-350	-417	-584	-414
Total Operating Income	-239	-125	-99	-98	-156	-221	-330	-351	-362	-344
Total Gross Profit	0.24	0.04	0.05	0.05	2.20	0.61	0.93	0.24	0.62	15
Total Revenue	0.24	0.04	0.05	0.05	2.20	0.61	0.93	0.24	0.62	15
Operating Revenue	0.24	0.04	0.05	0.05	2.20	0.61	0.93	0.24	0.62	15
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cost of Revenue	-	-	-	-	-	-	-	0.00	0.00	0.00
Total Operating Expenses	239	125	99	98	158	221	331	352	363	359
Selling, General & Admin Expense	228	95	57	43	46	71	135	103	130	169
Research & Development Expense	11	29	42	56	112	140	196	248	232	190
Impairment Charge	-	-	-	-	0.00	11	0.00	0.68	0.89	0.00
Total Other Income / (Expense), net	1.70	3.12	2.20	1.66	-4.01	-5.15	-20	-66	-222	-69
Interest Expense	0.00	0.07	0.62	0.43	5.92	9.07	15	64	129	154
Interest & Investment Income	2.99	3.10	2.67	1.86	2.44	2.44	-4.90	-15	-6.42	7.98
Other Income / (Expense), net	-1.29	0.09	0.16	0.24	-0.53	1.49	0.19	13	-86	77
Income Tax Expense	-0.30	-0.57	-0.49	-0.50	-0.11	-1.85	0.01	0.03	-0.04	0.00
Net Income / (Loss) Attributable to Noncontrolling Interest	-	-	-	-	-2.38	-2.34	-3.06	-0.75	-0.66	-0.08
Basic Earnings per Share	($3.31)	($1.47)	($1.20)	($1.22)	($0.43)	($0.59)	($0.89)	($1.04)	($1.15)	($0.59)
Weighted Average Basic Shares Outstanding	71.52M	81.98M	80.58M	79.13M	366.32M	377.07M	389.23M	399.90M	508.64M	697.31M
Diluted Earnings per Share	($3.31)	($1.47)	($1.20)	($1.22)	($0.43)	($0.59)	($0.89)	($1.04)	($1.15)	($0.62)
Weighted Average Diluted Shares Outstanding	71.52M	81.98M	80.58M	79.13M	366.32M	377.07M	389.23M	399.90M	508.64M	700.44M
Weighted Average Basic & Diluted Shares Outstanding	71.52M	81.98M	80.58M	79.13M	94.21M	103.55M	397.91M	435.84M	673.95M	853.44M

This table shows ImmunityBio's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-111	-108	-116	-138	-96	-233	-134	-135	-86	-59
Consolidated Net Income / (Loss)	-111	-108	-117	-138	-96	-233	-134	-135	-86	-59
Net Income / (Loss) Continuing Operations	-111	-108	-117	-138	-96	-233	-134	-135	-86	-59
Total Pre-Tax Income	-111	-108	-117	-138	-96	-233	-134	-135	-86	-59
Total Operating Income	-91	-85	-112	-85	-80	-85	-95	-99	-80	-69
Total Gross Profit	0.12	0.07	0.36	0.04	0.08	0.14	0.04	1.05	6.11	7.55
Total Revenue	0.12	0.07	0.36	0.04	0.08	0.14	0.04	1.05	6.11	7.55
Operating Revenue	0.12	0.07	0.36	0.04	0.08	0.14	0.04	1.05	6.11	7.55
Total Operating Expenses	91	85	112	85	80	86	95	100	86	77
Selling, General & Admin Expense	19	26	33	32	32	33	42	49	36	42
Research & Development Expense	72	58	79	53	48	52	53	51	50	35
Total Other Income / (Expense), net	-20	-23	-5.00	-53	-16	-148	-39	-35	-5.50	10
Interest Expense	17	29	30	32	35	32	37	39	40	38
Interest & Investment Income	-3.60	-7.37	-1.66	-4.02	-1.22	0.48	3.10	1.89	1.80	1.19
Other Income / (Expense), net	0.01	13	26	-17	21	-116	-4.55	1.88	33	47
Net Income / (Loss) Attributable to Noncontrolling Interest	-0.22	-0.11	-0.24	-0.33	-0.06	-0.02	-0.02	-0.02	-0.02	-0.02
Basic Earnings per Share	($0.28)	($0.26)	($0.27)	($0.32)	($0.19)	($0.37)	($0.20)	($0.20)	($0.12)	($0.07)
Weighted Average Basic Shares Outstanding	400.06M	399.90M	428.38M	437.46M	498.38M	508.64M	672.83M	686.94M	695.90M	697.31M
Diluted Earnings per Share	($0.28)	($0.26)	($0.27)	($0.32)	($0.19)	($0.37)	($0.20)	($0.20)	($0.14)	($0.08)
Weighted Average Diluted Shares Outstanding	400.06M	399.90M	428.38M	437.46M	498.38M	508.64M	672.83M	686.94M	697.96M	700.44M
Weighted Average Basic & Diluted Shares Outstanding	400.30M	435.84M	435.98M	456.25M	667.71M	673.95M	691.57M	696.53M	696.83M	853.44M

This table details how cash moves in and out of ImmunityBio's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	117	-168	16	-7.05	-19	-41	146	-76	161	-122
Net Cash From Operating Activities	-25	-39	-49	-63	-152	-172	-274	-338	-367	-391
Net Cash From Continuing Operating Activities	-25	-39	-49	-63	-152	-172	-274	-338	-367	-391
Net Income / (Loss) Continuing Operations	-237	-121	-96	-96	-160	-224	-350	-417	-584	-414
Consolidated Net Income / (Loss)	-237	-121	-96	-96	-160	-224	-350	-417	-584	-414
Depreciation Expense	1.47	3.61	5.57	9.56	14	13	14	18	19	18
Amortization Expense	0.04	2.18	1.60	0.46	-	0.79	0.47	18	42	21
Non-Cash Adjustments To Reconcile Net Income	210	73	38	23	6.38	23	69	50	151	-1.64
Changes in Operating Assets and Liabilities, net	-0.02	3.27	2.58	0.05	-12	16	-8.18	-6.51	4.70	-15
Net Cash From Investing Activities	-175	-114	100	57	19	-20	-85	27	-30	-12
Net Cash From Continuing Investing Activities	-175	-114	100	57	19	-20	-85	27	-30	-12
Purchase of Property, Plant & Equipment	-2.24	-6.56	-35	-13	-4.29	-1.67	-34	-78	-31	-6.89
Acquisitions	-1.82	-	-	-	-	0.00	0.00	-22	0.00	-1.00
Purchase of Investments	-198	-273	-111	-95	-87	-92	-142	-34	-10	-141
Sale and/or Maturity of Investments	27	166	254	165	112	74	70	162	10	137
Net Cash From Financing Activities	317	-16	-35	-0.77	114	151	505	234	558	282
Net Cash From Continuing Financing Activities	317	-16	-35	-0.77	114	151	505	234	558	282
Repayment of Debt	-0.13	-0.03	-20	-0.48	48	-	339	174	259	0.00
Issuance of Debt	-	-	-	-	-	64	0.00	0.00	193	97
Issuance of Common Equity	316	-	1.22	0.00	30	86	166	60	110	111
Other Financing Activities, net	5.81	0.32	-1.04	-0.07	39	0.67	0.98	-0.94	-3.23	73
Cash Interest Paid	0.00	0.07	0.67	0.48	0.02	0.04	2.11	35	77	92
Cash Income Taxes Paid	0.00	0.00	0.00	0.00	0.00	0.01	0.01	0.00	0.01	0.02

This table details how cash moves in and out of ImmunityBio's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	42	0.48	-16	-45	134	87	-132	-2.97	-18	32
Net Cash From Operating Activities	-81	-91	-84	-80	-87	-115	-107	-100	-99	-85
Net Cash From Continuing Operating Activities	-81	-91	-84	-80	-87	-116	-107	-99	-100	-85
Net Income / (Loss) Continuing Operations	-111	-108	-117	-138	-96	-233	-134	-135	-86	-59
Consolidated Net Income / (Loss)	-111	-108	-117	-138	-96	-233	-134	-135	-86	-59
Depreciation Expense	4.50	5.23	4.68	4.68	4.59	4.56	4.56	4.41	4.46	4.14
Amortization Expense	4.51	11	12	12	11	7.00	5.06	5.44	5.62	4.98
Non-Cash Adjustments To Reconcile Net Income	13	7.94	-12	31	-0.27	132	20	21	-18	-26
Changes in Operating Assets and Liabilities, net	8.71	-6.61	28	10	-7.52	-26	-2.76	4.27	-6.55	-9.57
Net Cash From Investing Activities	-1.17	-19	-8.48	-8.60	-16	2.25	-36	-51	65	9.83
Net Cash From Continuing Investing Activities	-1.17	-19	-8.48	-8.60	-16	2.25	-36	-51	65	9.83
Purchase of Property, Plant & Equipment	-16	-19	-8.43	-8.53	-5.68	-7.96	-1.26	-0.72	-2.79	-2.11
Purchase of Investments	-0.09	-0.02	-0.16	-0.08	-9.96	-0.17	-48	-86	-0.75	-6.09
Sale and/or Maturity of Investments	15	0.06	0.10	-	-	10	14	35	70	18
Net Cash From Financing Activities	124	110	77	43	238	201	10	149	16	107
Net Cash From Continuing Financing Activities	124	110	77	43	238	201	10	149	16	107
Issuance of Common Equity	-	60	47	14	40	9.36	0.00	3.63	-	108
Other Financing Activities, net	-0.39	-0.24	-0.25	0.06	-1.45	-1.58	10	48	16	-0.80
Cash Interest Paid	9.85	14	16	10	7.38	44	24	24	24	21

This table presents ImmunityBio's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	367	317	250	182	143	221	469	362	504	383
Total Current Assets	298	205	132	89	56	112	334	141	294	185
Cash & Equivalents	176	8.08	24	17	16	35	181	105	265	143
Short-Term Investments	118	191	104	57	36	61	136	2.54	1.01	6.38
Accounts Receivable	0.22	1.09	0.15	-	-	2.00	1.33	1.89	2.02	2.65
Inventories, net	-	-	-	-	-	-	-	-	0.00	8.27
Prepaid Expenses	3.11	5.14	4.15	14	4.11	14	16	32	26	24
Plant, Property, & Equipment, net	5.52	19	77	77	61	73	83	144	146	137
Total Noncurrent Assets	64	93	41	16	27	37	52	78	64	61
Long-Term Investments	55	88	30	5.70	1.50	0.95	0.82	0.84	0.89	0.00
Noncurrent Note & Lease Receivables	-	-	-	-	-	6.13	6.38	6.63	6.88	7.13
Goodwill	-	-	-	-	-	-	-	-	17	16
Other Noncurrent Operating Assets	1.36	0.79	8.83	10	25	29	43	51	39	38
Total Liabilities & Shareholders' Equity	367	317	250	182	143	221	469	362	504	383
Total Liabilities	11	24	32	36	22	340	713	812	1,090	871
Total Current Liabilities	6.15	13	21	27	12	68	369	501	58	55
Accounts Payable	3.44	5.80	8.23	4.49	2.24	63	67	66	53	47
Other Current Liabilities	0.14	0.89	1.37	1.67	3.98	5.02	3.01	2.65	5.24	7.47
Total Noncurrent Liabilities	4.71	12	11	8.68	11	272	344	311	1,032	816
Long-Term Debt	-	-	-	-	-	254	306	241	837	284
Other Noncurrent Operating Liabilities	0.00	2.27	2.00	5.95	11	17	37	70	195	532
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	356	293	219	146	121	-118	-244	-450	-586	-488
Total Preferred & Common Equity	356	293	219	146	121	-120	-242	-447	-587	-489
Total Common Equity	356	293	219	146	121	-120	-242	-447	-587	-489
Common Stock	607	681	718	741	783	1,495	1,720	1,931	2,375	2,885
Retained Earnings	-250	-387	-499	-595	-662	-1,615	-1,962	-2,378	-2,962	-3,375
Accumulated Other Comprehensive Income / (Loss)	-0.19	-0.28	-0.38	-0.27	-0.11	0.12	0.00	0.18	0.01	1.20
Noncontrolling Interest	-	-	-	-	-	1.32	-1.74	-2.49	1.05	0.97

This table presents ImmunityBio's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	353	343	291	432	401	444	365
Total Current Assets	143	113	67	215	196	243	163
Cash & Equivalents	104	88	44	178	133	130	112
Short-Term Investments	6.90	2.79	2.45	12	37	88	18
Accounts Receivable	1.49	1.46	2.03	2.33	2.14	2.06	4.90
Inventories, net	-	-	-	-	-	1.81	1.96
Prepaid Expenses	31	21	19	23	23	21	26
Plant, Property, & Equipment, net	130	154	151	152	144	142	139
Total Noncurrent Assets	79	76	73	65	61	60	62
Long-Term Investments	0.81	0.82	0.84	0.82	0.00	0.00	0.00
Noncurrent Note & Lease Receivables	6.57	6.69	6.75	6.82	6.94	7.00	7.07
Goodwill	-	-	-	-	-	-	16
Other Noncurrent Operating Assets	52	49	46	39	38	36	39
Total Liabilities & Shareholders' Equity	353	343	291	432	401	444	365
Total Liabilities	782	875	936	843	1,092	1,142	1,109
Total Current Liabilities	71	565	613	90	54	62	61
Accounts Payable	69	91	89	86	48	56	54
Other Current Liabilities	1.37	2.84	43	4.36	6.08	6.25	7.03
Total Noncurrent Liabilities	711	310	323	753	1,038	1,080	1,048
Long-Term Debt	661	246	250	645	851	956	973
Other Noncurrent Operating Liabilities	50	65	73	107	187	123	75
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-429	-532	-645	-411	-691	-697	-744
Total Preferred & Common Equity	-427	-529	-642	-412	-692	-698	-745
Total Common Equity	-427	-529	-642	-412	-692	-698	-745
Common Stock	1,844	1,966	1,991	2,316	2,404	2,532	2,571
Retained Earnings	-2,270	-2,495	-2,633	-2,728	-3,096	-3,230	-3,316
Accumulated Other Comprehensive Income / (Loss)	-0.19	-0.03	-0.04	0.79	-0.01	-0.01	0.10
Noncontrolling Interest	-2.38	-2.73	-3.07	1.07	1.03	1.01	0.99

This table displays calculated financial ratios and metrics derived from ImmunityBio's official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-63.18%	-81.36%	2.27%	4.44%	4,585.11%	-72.53%	54.38%	-74.30%	159.17%	2,270.58%
EBITDA Growth	-4,437.17%	50.30%	22.61%	3.99%	-61.96%	-44.22%	-53.20%	4.02%	-28.01%	41.00%
EBIT Growth	-4,089.17%	48.20%	20.46%	0.82%	-59.74%	-39.93%	-50.45%	-2.57%	-32.40%	40.37%
NOPAT Growth	-4,184.77%	47.88%	20.39%	0.74%	-58.81%	-41.36%	-49.53%	-6.36%	-3.12%	4.99%
Net Income Growth	-3,729.85%	49.00%	20.19%	0.20%	-66.44%	-39.98%	-56.05%	-19.29%	-39.91%	29.15%
EPS Growth	-341.33%	55.59%	18.37%	-1.67%	64.75%	-37.21%	-50.85%	-16.85%	-10.58%	46.09%
Operating Cash Flow Growth	-348.03%	-52.51%	-26.40%	-29.93%	-139.99%	-12.90%	-59.80%	-22.99%	-8.67%	-6.67%
Free Cash Flow Firm Growth	-8,311.25%	49.12%	-35.52%	43.79%	-60.44%	-13.71%	-87.46%	-34.49%	61.60%	178.97%
Invested Capital Growth	610.36%	38.06%	424.78%	0.23%	2.08%	-42.47%	12.57%	163.70%	-114.17%	-2,063.88%
Revenue Q/Q Growth	0.00%	-2.22%	-4.26%	-9.62%	5,270.73%	-79.28%	135.26%	-56.91%	11.87%	101.10%
EBITDA Q/Q Growth	0.00%	5.38%	-0.65%	8.71%	-139.55%	14.13%	-3.60%	6.03%	-52.95%	43.58%
EBIT Q/Q Growth	0.00%	3.73%	-0.01%	7.02%	-126.41%	14.80%	-3.83%	2.02%	-40.60%	40.11%
NOPAT Q/Q Growth	0.00%	3.70%	-0.25%	7.24%	-125.10%	14.40%	-3.73%	-1.63%	-0.14%	4.44%
Net Income Q/Q Growth	0.00%	2.09%	-0.26%	6.91%	-137.31%	15.60%	-7.03%	-4.19%	-27.27%	29.64%
EPS Q/Q Growth	0.00%	-7.30%	-1.69%	6.87%	44.16%	-103.45%	-5.95%	-2.97%	-10.58%	31.87%
Operating Cash Flow Q/Q Growth	-47.03%	0.49%	-6.29%	-0.62%	-151.38%	21.86%	-5.39%	-5.99%	-7.17%	7.15%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	-17.28%	24.90%	-114.94%	26.37%	-20.34%	3.77%	31.19%	131.43%
Invested Capital Q/Q Growth	0.00%	2.31%	38.07%	1.05%	-1.28%	-33.94%	36.15%	-3.98%	-137.09%	-459.85%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-101,125.00%	-269,597.73%	-204,000.00%	-187,521.28%	-6,482.43%	-34,026.61%	-33,767.02%	-126,130.83%	-62,299.84%	-1,550.63%
Operating Margin	-101,218.64%	-282,954.55%	-220,266.67%	-209,338.30%	-7,095.87%	-36,509.09%	-35,361.88%	-146,374.17%	-58,239.55%	-2,334.23%
EBIT Margin	-101,764.83%	-282,754.55%	-219,917.78%	-208,836.17%	-7,120.12%	-36,263.47%	-35,341.22%	-141,072.50%	-72,070.10%	-1,812.77%
Profit (Net Income) Margin	-100,371.19%	-274,565.91%	-214,273.33%	-204,736.17%	-7,273.30%	-37,055.70%	-37,456.96%	-173,883.33%	-93,866.88%	-2,805.32%
Tax Burden Percent	99.87%	99.53%	99.49%	99.48%	99.93%	99.18%	100.00%	100.01%	99.99%	100.00%
Interest Burden Percent	98.76%	97.56%	97.93%	98.55%	102.22%	103.03%	105.98%	123.25%	130.25%	154.75%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-4,565.55%	-803.71%	-176.60%	-104.23%	-163.63%	-290.68%	-559.89%	-309.20%	-512.32%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-4,532.36%	-792.98%	-164.13%	-80.72%	-87.27%	-424.22%	-613.22%	-349.40%	-570.54%	0.00%
Return on Net Nonoperating Assets (RNNOA)	4,454.64%	766.50%	138.95%	51.48%	43.52%	-20,192.37%	752.96%	429.51%	625.06%	0.00%
Return on Equity (ROE)	-110.91%	-37.21%	-37.65%	-52.75%	-120.11%	-20,483.05%	193.07%	120.31%	112.74%	77.02%
Cash Return on Invested Capital (CROIC)	-1,955.08%	-835.68%	-312.58%	-104.46%	-165.69%	-236.77%	-571.71%	-399.22%	0.00%	0.00%
Operating Return on Assets (OROA)	-112.60%	-36.36%	-34.85%	-45.40%	-96.46%	-120.38%	-95.64%	-81.46%	-103.43%	-60.24%
Return on Assets (ROA)	-111.06%	-35.31%	-33.96%	-44.51%	-98.54%	-123.01%	-101.36%	-100.41%	-134.71%	-93.23%
Return on Common Equity (ROCE)	-110.91%	-37.21%	-37.65%	-52.75%	-120.11%	-8,150.18%	192.85%	119.58%	112.58%	77.17%
Return on Equity Simple (ROE_SIMPLE)	-66.54%	-41.17%	-44.06%	-65.91%	-132.71%	187.12%	144.46%	93.29%	99.47%	84.57%
Net Operating Profit after Tax (NOPAT)	-167	-87	-69	-69	-109	-155	-231	-246	-254	-241
NOPAT Margin	-70,853.05%	-198,068.18%	-154,186.67%	-146,536.81%	-4,967.11%	-25,556.36%	-24,753.32%	-102,461.92%	-40,767.68%	-1,633.96%
Net Nonoperating Expense Percent (NNEP)	-33.19%	-10.72%	-12.47%	-23.51%	-76.36%	133.54%	53.33%	40.20%	58.21%	49.05%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-110.10%	-101.02%	118.26%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	96,473.73%	216,797.73%	126,935.56%	90,889.36%	2,109.72%	11,788.10%	14,481.37%	42,795.00%	20,839.23%	1,144.68%
R&D to Revenue	4,844.92%	66,256.82%	93,431.11%	118,548.94%	5,086.15%	23,059.01%	20,980.51%	103,395.42%	37,357.88%	1,289.55%
Operating Expenses to Revenue	101,318.64%	283,054.55%	220,366.67%	209,438.30%	7,195.87%	36,609.09%	35,461.88%	146,474.17%	58,339.55%	2,434.23%
Earnings before Interest and Taxes (EBIT)	-240	-124	-99	-98	-157	-219	-330	-339	-448	-267
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-239	-119	-92	-88	-143	-206	-315	-303	-388	-229
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.95	1.61	1.63	0.63	3.09	0.00	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	4.04	1.63	1.65	0.63	3.09	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	5,964.19	10,708.81	7,927.86	1,955.37	169.31	2,392.63	2,588.20	8,456.42	5,388.88	120.98
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	116.43	15.13	3.09	0.18	4.73	41.34	61.81	22.48	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	4,494.34	4,326.06	4,531.35	256.43	145.17	2,654.87	2,894.31	10,800.82	6,306.32	130.18
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	19.94
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.01	0.02	0.02	0.00	0.00	-2.15	-2.48	-1.50	-1.43	-0.58
Long-Term Debt to Equity	0.01	0.02	0.02	0.00	0.00	-2.15	-1.26	-0.54	-1.43	-0.58
Financial Leverage	-0.98	-0.97	-0.85	-0.64	-0.50	47.60	-1.23	-1.23	-1.10	-0.66
Leverage Ratio	1.00	1.05	1.11	1.19	1.22	166.52	-1.90	-1.20	-0.84	-0.83
Compound Leverage Factor	0.99	1.03	1.09	1.17	1.25	171.56	-2.02	-1.48	-1.09	-1.28
Debt to Total Capital	0.69%	1.89%	2.19%	0.00%	0.00%	187.21%	167.44%	301.40%	333.43%	-139.60%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	82.74%	193.37%	0.00%	0.00%
Long-Term Debt to Total Capital	0.69%	1.89%	2.19%	0.00%	0.00%	187.21%	84.70%	108.02%	333.43%	-139.60%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.97%	-0.48%	-1.12%	0.42%	-0.48%
Common Equity to Total Capital	99.31%	98.11%	97.81%	100.00%	100.00%	-88.18%	-66.96%	-200.28%	-233.85%	240.08%
Debt to EBITDA	-0.01	-0.05	-0.05	0.00	0.00	-1.24	-1.92	-2.22	-2.16	-1.24
Net Debt to EBITDA	1.45	2.37	1.67	0.00	0.00	-0.76	-0.91	-1.87	-1.47	-0.59
Long-Term Debt to EBITDA	-0.01	-0.05	-0.05	0.00	0.00	-1.24	-0.97	-0.80	-2.16	-1.24
Debt to NOPAT	-0.01	-0.06	-0.07	0.00	0.00	-1.65	-2.62	-2.74	-3.30	-1.18
Net Debt to NOPAT	2.07	3.22	2.20	0.00	0.00	-1.02	-1.24	-2.30	-2.25	-0.56
Long-Term Debt to NOPAT	-0.01	-0.06	-0.07	0.00	0.00	-1.65	-1.33	-0.98	-3.30	-1.18
Altman Z-Score	75.65	9.47	3.22	-4.42	0.26	-10.69	-6.23	-11.97	-8.75	-12.97
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	60.21%	0.12%	0.61%	0.14%	-0.19%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	48.40	16.34	6.35	3.26	4.82	1.64	0.91	0.28	5.05	3.36
Quick Ratio	47.89	15.93	6.15	2.75	4.47	1.44	0.86	0.22	4.61	2.77
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-178	-91	-123	-69	-111	-126	-236	-318	-122	96
Operating Cash Flow to CapEx	-1,129.18%	-588.31%	-140.11%	-499.46%	-3,721.78%	-10,289.04%	-2,100.41%	-431.81%	-1,199.18%	-5,679.97%
Free Cash Flow to Firm to Interest Expense	0.00	-1,372.98	-198.72	-159.42	-18.71	-13.88	-15.90	-5.00	-0.94	0.62
Operating Cash Flow to Interest Expense	0.00	-584.74	-78.93	-146.38	-25.69	-18.92	-18.48	-5.31	-2.84	-2.54
Operating Cash Flow Less CapEx to Interest Expense	0.00	-684.14	-135.27	-175.68	-26.38	-19.11	-19.36	-6.54	-3.08	-2.58
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.00	0.00	0.03
Accounts Receivable Turnover	0.00	0.07	0.07	0.00	0.00	0.00	0.56	0.15	0.32	6.31
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.08	0.00	0.00	0.00	0.03	0.01	0.01	0.00	0.00	0.10
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	5,416.93	5,041.06	0.00	0.00	0.00	651.84	2,450.82	1,146.93	57.83
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	5,416.93	5,041.06	0.00	0.00	0.00	651.84	2,450.82	1,146.93	57.83
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	9.11	13	66	66	68	39	44	115	-16	-354
Invested Capital Turnover	0.06	0.00	0.00	0.00	0.03	0.01	0.02	0.00	0.01	-0.08
Increase / (Decrease) in Invested Capital	11	3.47	53	0.16	1.37	-29	4.88	72	-132	-337
Enterprise Value (EV)	1,061	190	204	12	320	1,606	2,703	2,592	3,923	1,919
Market Capitalization	1,408	471	357	92	373	1,448	2,417	2,030	3,352	1,784
Book Value per Share	$4.38	$3.56	$2.75	$1.84	$1.23	($1.10)	($0.61)	($1.12)	($0.88)	($0.70)
Tangible Book Value per Share	$4.29	$3.50	$2.72	$1.84	$1.23	($1.12)	($0.61)	($1.17)	($0.90)	($0.72)
Total Capital	358	299	224	146	121	136	362	223	251	-204
Total Debt	2.47	5.65	4.91	0.00	0.00	254	606	673	837	284
Total Long-Term Debt	2.47	5.65	4.91	0.00	0.00	254	306	241	837	284
Net Debt	-347	-281	-153	-80	-53	157	288	565	570	135
Capital Expenditures (CapEx)	2.24	6.56	35	13	4.09	1.67	13	78	31	6.89
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-2.83	-6.33	-17	-13	-7.45	-52	-53	-36	-31	-20
Debt-free Net Working Capital (DFNWC)	291	193	112	62	44	44	265	72	236	130
Net Working Capital (NWC)	291	193	112	62	44	44	-35	-360	236	130
Net Nonoperating Expense (NNE)	70	34	27	27	51	70	119	171	330	173
Net Nonoperating Obligations (NNO)	-347	-281	-153	-80	-53	157	288	565	570	135
Total Depreciation and Amortization (D&A)	1.51	5.79	7.16	10	14	14	15	36	61	39
Debt-free, Cash-free Net Working Capital to Revenue	-1,197.46%	-14,384.09%	-36,804.44%	-26,887.23%	-338.51%	-8,674.71%	-5,623.98%	-14,819.58%	-4,929.42%	-136.77%
Debt-free Net Working Capital to Revenue	123,471.19%	437,709.09%	247,977.78%	130,876.60%	2,007.18%	7,203.14%	28,328.48%	29,840.42%	37,910.13%	879.23%
Net Working Capital to Revenue	123,471.19%	437,709.09%	247,977.78%	130,876.60%	2,007.18%	7,203.14%	-3,709.64%	-150,118.33%	37,910.13%	879.23%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($3.31)	($1.47)	($1.20)	($1.22)	($0.70)	($0.89)	($0.89)	($1.04)	($1.15)	($0.59)
Adjusted Weighted Average Basic Shares Outstanding	81.93M	82.30M	79.03M	79.09M	98.48M	109.34M	389.23M	399.90M	508.64M	697.31M
Adjusted Diluted Earnings per Share	($3.31)	($1.47)	($1.20)	($1.22)	($0.70)	($0.89)	($0.89)	($1.04)	($1.15)	($0.62)
Adjusted Weighted Average Diluted Shares Outstanding	81.93M	82.30M	79.03M	79.09M	98.48M	109.34M	389.23M	399.90M	508.64M	700.44M
Adjusted Basic & Diluted Earnings per Share	($3.31)	($1.47)	($1.20)	($1.22)	($0.70)	($0.89)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	71.52M	81.98M	80.58M	79.13M	94.21M	103.55M	397.91M	435.84M	673.95M	853.44M
Normalized Net Operating Profit after Tax (NOPAT)	-167	-87	-69	-69	-109	-147	-231	-245	-253	-241
Normalized NOPAT Margin	-70,853.05%	-198,068.18%	-154,186.67%	-146,536.81%	-4,967.11%	-24,322.98%	-24,753.32%	-102,263.29%	-40,667.97%	-1,633.96%
Pre Tax Income Margin	-100,498.73%	-275,865.91%	-215,368.89%	-205,806.38%	-7,278.07%	-37,360.83%	-37,456.00%	-173,869.17%	-93,873.31%	-2,805.32%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	-1,885.03	-160.13	-226.68	-26.48	-24.18	-22.23	-5.33	-3.47	-1.73
NOPAT to Interest Expense	0.00	-1,320.45	-112.27	-159.06	-18.48	-17.04	-15.57	-3.87	-1.96	-1.56
EBIT Less CapEx to Interest Expense	0.00	-1,984.42	-216.47	-255.99	-27.17	-24.36	-23.11	-6.56	-3.71	-1.78
NOPAT Less CapEx to Interest Expense	0.00	-1,419.85	-168.61	-188.37	-19.17	-17.22	-16.45	-5.10	-2.20	-1.61
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-2.03%	-13.12%	-15.79%	-0.24%	-1.56%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from ImmunityBio's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	78.79%	-81.28%	2,471.43%	17.14%	-30.51%	90.41%	-88.89%	2,453.66%	7,346.34%	5,333.09%
EBITDA Growth	-8.80%	25.73%	24.73%	-15.93%	46.96%	-239.15%	-30.84%	-3.09%	14.18%	92.81%
EBIT Growth	-15.12%	8.79%	11.33%	-28.35%	34.58%	-178.89%	-17.20%	4.42%	20.37%	88.71%
NOPAT Growth	-15.18%	-7.10%	-16.26%	-6.94%	11.75%	-0.58%	14.68%	-16.66%	-0.15%	18.72%
Net Income Growth	-25.71%	-18.32%	-13.19%	-45.74%	13.96%	-115.47%	-15.05%	2.63%	10.34%	74.65%
EPS Growth	-27.27%	-13.04%	-3.85%	-33.33%	32.14%	-42.31%	25.93%	37.50%	26.32%	78.38%
Operating Cash Flow Growth	-10.84%	-26.64%	-12.52%	12.58%	-8.44%	-27.05%	-26.89%	-25.79%	-13.00%	26.14%
Free Cash Flow Firm Growth	-431.83%	-117.02%	20.93%	105.72%	113.17%	154.87%	140.43%	-1,080.82%	-653.00%	301.45%
Invested Capital Growth	273.90%	163.70%	19.19%	-62.53%	-63.32%	-114.17%	-111.76%	2.21%	123.03%	-2,063.88%
Revenue Q/Q Growth	237.14%	-38.14%	393.15%	-88.61%	100.00%	69.51%	-71.22%	2,517.50%	483.19%	23.68%
EBITDA Q/Q Growth	-11.57%	31.41%	-22.80%	-23.38%	48.96%	-338.59%	52.63%	2.79%	57.51%	63.28%
EBIT Q/Q Growth	-14.30%	20.30%	-17.61%	-19.81%	41.74%	-239.75%	50.58%	2.29%	51.46%	51.82%
NOPAT Q/Q Growth	-14.04%	6.50%	-31.43%	23.69%	5.88%	-6.56%	-11.49%	-4.35%	19.21%	13.52%
Net Income Q/Q Growth	-17.22%	2.55%	-7.62%	-18.55%	30.80%	-144.05%	42.54%	-0.34%	36.28%	30.99%
EPS Q/Q Growth	-16.67%	7.14%	-3.85%	-18.52%	40.63%	-94.74%	45.95%	0.00%	30.00%	42.86%
Operating Cash Flow Q/Q Growth	11.67%	-12.56%	7.07%	5.38%	-9.56%	-31.88%	7.19%	6.20%	1.58%	13.79%
Free Cash Flow Firm Q/Q Growth	-20.64%	13.54%	28.92%	107.71%	178.00%	260.21%	-47.63%	-287.02%	-56.74%	361.49%
Invested Capital Q/Q Growth	12.46%	-3.98%	-19.09%	-57.11%	10.08%	-137.09%	32.82%	472.66%	140.19%	-459.85%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-69,313.56%	-76,845.21%	-19,135.00%	-207,292.68%	-52,900.00%	-136,871.22%	-225,322.50%	-8,367.91%	-609.71%	-181.02%
Operating Margin	-76,952.54%	-116,301.37%	-30,994.44%	-207,670.73%	-97,726.83%	-61,430.94%	-237,990.00%	-9,487.39%	-1,314.33%	-918.96%
EBIT Margin	-76,947.46%	-99,127.40%	-23,639.72%	-248,682.93%	-72,440.24%	-145,188.49%	-249,355.00%	-9,308.12%	-774.70%	-301.80%
Profit (Net Income) Margin	-94,204.24%	-148,391.78%	-32,384.17%	-337,104.88%	-116,636.59%	-167,923.74%	-335,325.00%	-12,854.25%	-1,404.39%	-783.62%
Tax Burden Percent	100.00%	100.03%	100.00%	100.00%	100.00%	99.98%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	122.43%	149.65%	136.99%	135.56%	161.01%	115.68%	134.48%	138.10%	181.28%	259.65%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-394.20%	-245.67%	-148.18%	-1,172.33%	-463.40%	-540.40%	-1,222.06%	-214.69%	-94.81%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-406.54%	-257.14%	-155.57%	-1,185.28%	-471.28%	-571.00%	-1,232.41%	-223.83%	-99.37%	0.00%
Return on Net Nonoperating Assets (RNNOA)	506.52%	316.10%	186.28%	1,348.35%	563.41%	625.58%	1,315.40%	237.33%	111.62%	0.00%
Return on Equity (ROE)	112.32%	70.43%	38.10%	176.02%	100.01%	85.18%	93.34%	22.63%	16.80%	77.02%
Cash Return on Invested Capital (CROIC)	-433.50%	-399.22%	-316.85%	-264.16%	-215.87%	0.00%	0.00%	-625.11%	-430.53%	0.00%
Operating Return on Assets (OROA)	-151.08%	-57.24%	-37.80%	-483.53%	-102.57%	-208.37%	-202.41%	-33.10%	-14.25%	-10.03%
Return on Assets (ROA)	-184.97%	-85.69%	-51.78%	-655.45%	-165.15%	-241.00%	-272.20%	-45.72%	-25.84%	-26.04%
Return on Common Equity (ROCE)	111.62%	70.00%	37.90%	175.16%	99.85%	85.06%	93.21%	22.60%	16.83%	77.17%
Return on Equity Simple (ROE_SIMPLE)	93.87%	0.00%	81.46%	73.86%	111.43%	0.00%	86.91%	85.59%	78.89%	0.00%
Net Operating Profit after Tax (NOPAT)	-64	-59	-78	-60	-56	-60	-67	-70	-56	-49
NOPAT Margin	-53,866.78%	-81,410.96%	-21,696.11%	-145,369.51%	-68,408.78%	-43,001.65%	-166,593.00%	-6,641.17%	-920.03%	-643.27%
Net Nonoperating Expense Percent (NNEP)	12.34%	11.47%	7.39%	12.95%	7.88%	30.60%	10.34%	9.14%	4.56%	3.01%
Return On Investment Capital (ROIC_SIMPLE)	-	-26.61%	-	-	-	-23.81%	-	-	-	23.85%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	16,364.41%	35,910.96%	9,076.67%	78,092.68%	38,800.00%	23,820.14%	104,712.50%	4,704.01%	588.21%	552.58%
R&D to Revenue	60,688.14%	79,557.53%	22,017.78%	129,678.05%	59,026.83%	37,073.38%	133,377.50%	4,883.38%	826.12%	466.38%
Operating Expenses to Revenue	77,052.54%	116,401.37%	31,094.44%	207,770.73%	97,826.83%	61,530.94%	238,090.00%	9,587.39%	1,414.33%	1,018.96%
Earnings before Interest and Taxes (EBIT)	-91	-72	-85	-102	-59	-202	-100	-97	-47	-23
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-82	-56	-69	-85	-43	-190	-90	-88	-37	-14
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	3,571.83	8,456.42	1,353.62	2,047.36	1,386.80	5,388.88	11,983.85	3,341.52	353.40	120.98
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	21.12	22.48	15.17	47.33	27.85	0.00	0.00	124.93	34.96	0.00
Enterprise Value to Revenue (EV/Rev)	4,553.53	10,800.82	2,415.56	3,199.61	2,206.52	6,306.32	14,238.94	3,906.73	468.43	130.18
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	19.94
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	-1.54	-1.50	-1.35	-1.13	-1.57	-1.43	-1.23	-1.37	-1.31	-0.58
Long-Term Debt to Equity	-1.54	-0.54	-0.46	-0.39	-1.57	-1.43	-1.23	-1.37	-1.31	-0.58
Financial Leverage	-1.25	-1.23	-1.20	-1.14	-1.20	-1.10	-1.07	-1.06	-1.12	-0.66
Leverage Ratio	-0.92	-1.20	-0.84	-0.57	-0.94	-0.84	-0.61	-0.55	-0.69	-0.83
Compound Leverage Factor	-1.12	-1.79	-1.16	-0.77	-1.51	-0.97	-0.82	-0.76	-1.25	-2.15
Debt to Total Capital	284.97%	301.40%	386.79%	843.19%	274.99%	333.43%	533.17%	369.38%	425.51%	-139.60%
Short-Term Debt to Total Capital	0.00%	193.37%	254.30%	555.09%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	284.97%	108.02%	132.49%	288.09%	274.99%	333.43%	533.17%	369.38%	425.51%	-139.60%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	-1.03%	-1.12%	-1.47%	-3.53%	0.46%	0.42%	0.65%	0.39%	0.43%	-0.48%
Common Equity to Total Capital	-183.94%	-200.28%	-285.32%	-739.65%	-175.45%	-233.85%	-433.81%	-269.77%	-325.94%	240.08%
Debt to EBITDA	-2.05	-2.22	-2.56	-2.51	-2.55	-2.16	-2.08	-2.32	-2.40	-1.24
Net Debt to EBITDA	-1.70	-1.87	-2.23	-2.35	-1.79	-1.47	-1.66	-1.79	-2.08	-0.59
Long-Term Debt to EBITDA	-2.05	-0.80	-0.88	-0.86	-2.55	-2.16	-2.08	-2.32	-2.40	-1.24
Debt to NOPAT	-2.73	-2.74	-2.79	-2.81	-2.55	-3.30	-3.51	-3.79	-3.86	-1.18
Net Debt to NOPAT	-2.27	-2.30	-2.43	-2.63	-1.80	-2.25	-2.81	-2.93	-3.34	-0.56
Long-Term Debt to NOPAT	-2.73	-0.98	-0.96	-0.96	-2.55	-3.30	-3.51	-3.79	-3.86	-1.18
Altman Z-Score	-8.08	-9.54	-12.02	-15.29	-8.39	-7.13	-9.22	-8.11	-11.40	-10.86
Noncontrolling Interest Sharing Ratio	0.62%	0.61%	0.53%	0.49%	0.16%	0.14%	0.14%	0.15%	-0.18%	-0.19%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.02	0.28	0.20	0.11	2.38	5.05	3.64	3.91	2.68	3.36
Quick Ratio	1.59	0.22	0.16	0.08	2.13	4.61	3.21	3.54	2.22	2.77
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-152	-131	-93	7.18	20	72	38	-70	-110	289
Operating Cash Flow to CapEx	-505.80%	-479.25%	-1,000.36%	-935.64%	-1,540.14%	-1,449.04%	-8,483.90%	-13,860.08%	-3,537.36%	-4,033.35%
Free Cash Flow to Firm to Interest Expense	-9.04	-4.59	-3.12	0.22	0.57	2.24	1.00	-1.80	-2.74	7.68
Operating Cash Flow to Interest Expense	-4.81	-3.18	-2.83	-2.47	-2.50	-3.59	-2.85	-2.57	-2.45	-2.27
Operating Cash Flow Less CapEx to Interest Expense	-5.76	-3.84	-3.11	-2.74	-2.66	-3.84	-2.89	-2.59	-2.52	-2.32
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.03
Accounts Receivable Turnover	0.40	0.15	0.22	0.34	0.29	0.32	0.17	0.64	2.03	6.31
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.05	0.10
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	914.79	2,450.82	1,668.35	1,071.57	1,251.57	1,146.93	2,176.10	569.96	179.94	57.83
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	914.79	2,450.82	1,668.35	1,071.57	1,251.57	1,146.93	2,176.10	569.96	179.94	57.83
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	120	115	93	40	44	-16	-11	41	98	-354
Invested Capital Turnover	0.01	0.00	0.01	0.01	0.01	0.01	0.01	0.03	0.10	-0.08
Increase / (Decrease) in Invested Capital	88	72	15	-67	-76	-132	-104	0.89	54	-337
Enterprise Value (EV)	2,536	2,592	1,416	1,894	1,227	3,923	4,300	5,110	3,434	1,919
Market Capitalization	1,990	2,030	793	1,212	771	3,352	3,619	4,371	2,591	1,784
Book Value per Share	($1.07)	($1.12)	($1.21)	($1.47)	($0.90)	($0.88)	($1.03)	($1.01)	($1.07)	($0.70)
Tangible Book Value per Share	($1.12)	($1.17)	($1.26)	($1.52)	($0.94)	($0.90)	($1.05)	($1.03)	($1.09)	($0.72)
Total Capital	232	223	185	87	235	251	160	259	229	-204
Total Debt	661	673	717	732	645	837	851	956	973	284
Total Long-Term Debt	661	241	246	250	645	837	851	956	973	284
Net Debt	549	565	625	685	455	570	680	738	842	135
Capital Expenditures (CapEx)	16	19	8.43	8.53	5.68	7.96	1.26	0.72	2.79	2.11
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-39	-36	-71	-111	-65	-31	-29	-37	-28	-20
Debt-free Net Working Capital (DFNWC)	72	72	20	-65	125	236	142	181	102	130
Net Working Capital (NWC)	72	-360	-451	-547	125	236	142	181	102	130
Net Nonoperating Expense (NNE)	48	49	38	79	40	174	67	65	30	11
Net Nonoperating Obligations (NNO)	549	565	625	685	455	570	680	738	842	135
Total Depreciation and Amortization (D&A)	9.01	16	16	17	16	12	9.61	9.84	10	9.12
Debt-free, Cash-free Net Working Capital to Revenue	-6,966.79%	-14,819.58%	-12,158.53%	-18,701.52%	-11,697.48%	-4,929.42%	-9,447.68%	-2,848.55%	-384.30%	-136.77%
Debt-free Net Working Capital to Revenue	12,971.63%	29,840.42%	3,416.21%	-10,939.02%	22,438.49%	37,910.13%	47,007.62%	13,816.51%	1,393.75%	879.23%
Net Working Capital to Revenue	12,971.63%	-150,118.33%	-77,040.79%	-92,340.03%	22,438.49%	37,910.13%	47,007.62%	13,816.51%	1,393.75%	879.23%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.28)	($0.26)	($0.27)	($0.32)	($0.19)	($0.37)	($0.20)	($0.20)	($0.12)	($0.07)
Adjusted Weighted Average Basic Shares Outstanding	400.06M	399.90M	428.38M	437.46M	498.38M	508.64M	672.83M	686.94M	695.90M	697.31M
Adjusted Diluted Earnings per Share	($0.28)	($0.26)	($0.27)	($0.32)	($0.19)	($0.37)	($0.20)	($0.20)	($0.14)	($0.08)
Adjusted Weighted Average Diluted Shares Outstanding	400.06M	399.90M	428.38M	437.46M	498.38M	508.64M	672.83M	686.94M	697.96M	700.44M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	400.30M	435.84M	435.98M	456.25M	667.71M	673.95M	691.57M	696.53M	696.83M	853.44M
Normalized Net Operating Profit after Tax (NOPAT)	-64	-59	-78	-60	-56	-60	-67	-70	-56	-49
Normalized NOPAT Margin	-53,866.78%	-81,410.96%	-21,696.11%	-145,369.51%	-68,408.78%	-43,001.65%	-166,593.00%	-6,641.17%	-920.03%	-643.27%
Pre Tax Income Margin	-94,204.24%	-148,345.21%	-32,384.17%	-337,104.88%	-116,636.59%	-167,952.52%	-335,325.00%	-12,854.25%	-1,404.39%	-783.62%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-5.42	-2.53	-2.85	-3.16	-1.70	-6.28	-2.66	-2.50	-1.18	-0.61
NOPAT to Interest Expense	-3.79	-2.08	-2.62	-1.85	-1.60	-1.86	-1.78	-1.78	-1.40	-1.29
EBIT Less CapEx to Interest Expense	-6.37	-3.20	-3.14	-3.43	-1.86	-6.53	-2.69	-2.52	-1.24	-0.66
NOPAT Less CapEx to Interest Expense	-4.74	-2.74	-2.90	-2.11	-1.76	-2.11	-1.81	-1.80	-1.47	-1.35
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About ImmunityBio's Financials

When does ImmunityBio's fiscal year end?

According to the most recent income statement we have on file, ImmunityBio's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has ImmunityBio's net income changed over the last 9 years?

ImmunityBio's net income appears to be on an upward trend, with a most recent value of -$413.65 million in 2024, rising from -$236.88 million in 2015. The previous period was -$583.85 million in 2023.

What is ImmunityBio's operating income?

ImmunityBio's total operating income in 2024 was -$344.18 million, based on the following breakdown:

Total Gross Profit: $14.75 million
Total Operating Expenses: $358.93 million

How has ImmunityBio revenue changed over the last 9 years?

Over the last 9 years, ImmunityBio's total revenue changed from $236 thousand in 2015 to $14.75 million in 2024, a change of 6,147.9%.

How much debt does ImmunityBio have?

ImmunityBio's total liabilities were at $871.06 million at the end of 2024, a 20.1% decrease from 2023, and a 7,925.3% increase since 2015.

How much cash does ImmunityBio have?

In the past 9 years, ImmunityBio's cash and equivalents has ranged from $8.08 million in 2016 to $265.45 million in 2023, and is currently $143.43 million as of their latest financial filing in 2024.

How has ImmunityBio's book value per share changed over the last 9 years?

Over the last 9 years, ImmunityBio's book value per share changed from 4.38 in 2015 to -0.70 in 2024, a change of -116.0%.

Related Companies

This page (NASDAQ:IBRX) was last updated on 4/26/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ImmunityBio (IBRX) Financials

Frequently Asked Questions About ImmunityBio's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ImmunityBio (IBRX) Financials

Annual Income Statements for ImmunityBio

Quarterly Income Statements for ImmunityBio

Annual Cash Flow Statements for ImmunityBio

Quarterly Cash Flow Statements for ImmunityBio

Annual Balance Sheets for ImmunityBio

Quarterly Balance Sheets for ImmunityBio

Annual Metrics and Ratios for ImmunityBio

Quarterly Metrics and Ratios for ImmunityBio

Frequently Asked Questions About ImmunityBio's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools